Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.

J Diabetes Investig · 2012 · PMC4015431 · PMID 24843617

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

There were highly significant differences in the change in HbA 1c between each alogliptin combination group and the glimepiride monotherapy group ( P < 0.0001), whilst the different dosages of alogliptin produced similar reductions in HbA 1c .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.